M3: Master Mitochondrial Modulators

One of the hallmarks of cancer is dysregulated metabolism. A substantial subset of many cancer types relies on a particular form of cellular energy for growth, called oxidative phposphorylation (OXPHOS). We are developing small-molecule drugs to inhibit OXPHOS in order to reduce cancer burden and improve quality of life.

CONTACT: Founder: Dr. Rebecca Laposa, Assistant Professor, Department of Pharmacology and Toxicology, rebecca.laposa@utoronto.ca